Research in DLBCL is ongoing, with a focus on understanding the molecular mechanisms driving the disease and developing targeted therapies. Recent advances include the use of CAR-T cell therapy, which involves modifying a patient's T-cells to attack the lymphoma cells. Other promising areas of research include novel monoclonal antibodies, small molecule inhibitors, and immunomodulatory agents. Clinical trials continue to play a crucial role in identifying new treatment options and improving patient outcomes.
